title: Polyhydroxybutyrate-coated magnetic nanoparticles for doxorubicin delivery: cytotoxic effect against doxorubicin-resistant breast cancer cell line.
abstract: In this study, polyhydroxybutyrate (PHB)-coated magnetic nanoparticles (MNPs) were prepared by coprecipitation of iron salts (Fe and Fe) by ammonium hydroxide. Characterizations of PHB-coated MNPs were performed by Fourier transform infrared spectroscopy, x-ray diffraction, dynamic light scattering, thermal gravimetric analysis, vibrating sample magnetometry, and transmission electron microscopy analyses. Doxorubicin was loaded onto PHB-MNPs, and the release efficiencies at different pHs were studied under in vitro conditions. The most efficient drug loading concentration was found about 87% at room temperature in phosphate-buffered saline (pH 7.2). The drug-loaded MNPs were stable up to 2 months in neutral pH for mimicking physiological conditions. The drug release studies were performed with acetate buffer (pH 4.5) that mimics endosomal pH. Doxorubicin (60%) released from PHB-MNPs within 65 hours. Doxorubicin-loaded PHB-MNPs were about 2.5-fold more cytotoxic as compared with free drug on resistant Michigan Cancer Foundation-7 (human breast adenocarcinoma, MCF-7) cell line (1 μM doxorubicin) in vitro. Therefore, doxorubicin-loaded PHB-MNPs lead to overcome the drug resistance.
authors.affiliation: 1Department of Food Engineering, Ahi Evran University, Kirşehir, Turkey; 2Department of Biotechnology, Middle East Technical University, Ankara, Turkey; and 3Central Labratory Molecular Biology and Biotechnology R&D, Middle East Technical University, Ankara, Turkey.
authors.forename: Serap
authors.initials: S
authors.lastname: Yalcin
authors.forename: Gozde
authors.initials: G
authors.lastname: Unsoy
authors.forename: Pelin
authors.initials: P
authors.lastname: Mutlu
authors.forename: Rouhollah
authors.initials: R
authors.lastname: Khodadust
authors.forename: Ufuk
authors.initials: U
authors.lastname: Gunduz
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D016503:Drug Delivery Systems; D065546:Drug Liberation; D019008:Drug Resistance, Neoplasm; D004355:Drug Stability; D004356:Drug Storage; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D006885:Hydroxybutyrates / Q000737:chemistry*; D061986:MCF-7 Cells; D058185:Magnetite Nanoparticles; D000091402:Prohibitins; D013997:Time Factors
chemical_list: D000903:Antibiotics, Antineoplastic; D006885:Hydroxybutyrates; D058185:Magnetite Nanoparticles; C000717328:PHB protein, human; D000091402:Prohibitins; D004317:Doxorubicin